Education and Training
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: PTX-022
Eligibility
Inclusion Criteria:
- Participants must be 13 years or older
- Diagnosed with Microcystic Lymphatic Malformations
- Able and willing to comply with all protocol-required activities
- Willing and able to provide written informed consent
Exclusion Criteria:
- Any significant concurrent condition that could adversely affect participation.
- Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications
or to PTX-022
- Patient's deemed by the investigator as unwilling or unable to remain compliant with
all tests and procedures, including adherence to study drug administration and other
protocol-required activities.
Ages Eligible for Study
13 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology Research
650-723-0636
I'm interested